Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. filed this Form 8-K on October 24, 2013, to report the entry into a material definitive agreement. The filing addresses a correction to the terms of the Company's 7.5% Convertible Senior Secured Notes due 2019.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, or liquidity metrics. The document focuses exclusively on a contractual amendment regarding debt conversion terms.
Material Changes
The Company entered into a supplemental indenture with U.S. Bank National Association to correct the maximum conversion rate for its 7.5% Convertible Senior Secured Notes due 2019. The correction aligns the Indenture with the Offering Memorandum dated April 25, 2013.
- Previous Indenture Rate: 188.7059 shares per $1,000 principal amount.
- Corrected Rate: 221.7294 shares per $1,000 principal amount (including shares delivered for the Interest Make-Whole Amount).
The Company noted that this corrected rate was previously disclosed in its Form 10-Q reports for the quarters ended March 31, 2013, and June 30, 2013.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of general business risks. The primary contingency addressed is the legal correction of the conversion share cap to ensure consistency with the original offering terms.
Investor Verification Checklist
- Verify the impact of the increased conversion rate (221.7294 shares vs. 188.7059 shares) on potential equity dilution.
- Confirm the terms of the 7.5% Convertible Senior Secured Notes due 2019 in the original Offering Memorandum dated April 25, 2013.
- Review the First Supplemental Indenture (Exhibit 4.1) for any additional covenants or conditions.